特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
246006

好酸球性食道炎:パイプライン製品の分析

Eosinophilic Esophagitis - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 131 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
好酸球性食道炎:パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 131 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

好酸球性食道炎とは、食物・アレルゲン・呑酸などに反応して、好酸球(白血球の一種)が食道組織内部に蓄積されるという症状です。主な症状として、体重減少や腹痛、吐き気・嘔吐、咳、胸焼け、胸痛などが挙げられます。危険因子には、免疫系の弱体化や、化学療法、アスピリン剤・抗炎症剤、慢性嘔吐、肥満、飲酒、喫煙などがあります。主な治療法には、抗ウイルス剤、抗真菌薬、鎮痛剤などが含まれています。

当レポートでは、世界各国での好酸球性食道炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

好酸球性食道炎の概要

治療薬の開発

  • 好酸球性食道炎向けパイプライン製品:概要
  • 各企業で開発中の好酸球性食道炎治療薬
  • 好酸球性食道炎治療薬:開発中の製品の一覧(企業別)

好酸球性食道炎:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

好酸球性食道炎治療薬の開発に従事している企業

  • Adare Pharmaceuticals Inc
  • Calypso Biotech SA
  • Celgene Corp
  • DBV Technologies SA
  • Dr. Falk Pharma GmbH
  • Quorum Innovations LLC
  • Regeneron Pharmaceuticals Inc
  • Shire Plc

薬剤のプロファイル

好酸球性食道炎治療薬:開発が休止状態の製品

好酸球性食道炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Eosinophilic Esophagitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Allakos Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Arena Pharmaceuticals Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H1 2020
  • Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2020
  • Eosinophilic Esophagitis - Pipeline by EsoCap AG, H1 2020
  • Eosinophilic Esophagitis - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Humanigen Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Kyowa Kirin Co Ltd, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Morphic Holding Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H1 2020
  • Eosinophilic Esophagitis - Pipeline by RAPT Therapeutics Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Eosinophilic Esophagitis - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Eosinophilic Esophagitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC12125IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2020, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 3, 2 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Eosinophilic Esophagitis - Overview
  • Eosinophilic Esophagitis - Therapeutics Development
  • Eosinophilic Esophagitis - Therapeutics Assessment
  • Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
  • Eosinophilic Esophagitis - Drug Profiles
  • Eosinophilic Esophagitis - Dormant Projects
  • Eosinophilic Esophagitis - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.